BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190118
DTEND;VALUE=DATE:20190220
DTSTAMP:20260729T230312
CREATED:20190118T054206Z
LAST-MODIFIED:20190118T054206Z
UID:21008-1547769600-1550620799@ces.b2sg.org
SUMMARY:Senior Drug Discovery Oncologist
DESCRIPTION:We are seeking a highly motivated and experienced Senior Scientist with deep expertise in oncology to join our Drug Discovery team. The successful candidate will have a track record of innovative and collaborative research\, demonstrated through project milestone delivery and peer-reviewed publications. The successful candidate is expected to be involved in significant interaction and collaboration within the company and with external KOLs/partners/CROs to support preclinical target validation and guide projects towards clinical development. \nResponsibilities: \n\nGuide research strategy and experimentation on small molecule oncology discovery programs\nAdvance oncology research programs from pre-clinical to clinical stage\nLead new target identification and validation efforts\nParticipate in multidisciplinary team efforts to make decisions on compound and program progression\nLead interactions with KOLs and serve as a disease biology expert on cross functional discovery teams\nStay informed on trends and emerging developments regarding research and development in the fields of oncology\n\nEssential Qualifications and Experience: \n\nPh.D. in cancer biology or related field with 8+ years postgraduate oncology drug discovery experience\nIn-depth knowledge/understanding of cancer pathways\, cellular and animal models across solid tumor and hematologic malignancies\, as well as various mechanisms of therapeutic response and resistance\nDemonstrated success as a lead biologist advancing novel scientific discoveries that impacted the course of clinical development\nExperience in managing external studies at CROs and academic collaborators including monitoring study execution and ensuring finalization of study reports within set timeline\nOutstanding presentation and communication skills\nSkilled at working in a multidisciplinary environment\n\nDesirable Skills: \n\nExperience on translational research\, IND-enabling studies\, as well as early clinical development\nKnowledge of epigenetics\, DNA damage repair\, cancer genetics\, and precision medicine\nProven record of innovative thinking to propose and champion new ideas and solve problems\nComfortable working across a number of disease areas and able to shift gears quickly. Must be open to change and the unknown with a creative and resourceful nature; a self-starter\, proactive and results-oriented with high performance standards
URL:https://ces.b2sg.org/event/schr-18jan19/
LOCATION:Schrödinger\, Inc.\, New York\, NY\, United States
CATEGORIES:Jobs
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2019/01/schrödinger-inc.jpg
END:VEVENT
END:VCALENDAR